PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-89.95%
Negative EBIT growth while TRVN is at 14.24%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-95.43%
Negative operating income growth while TRVN is at 14.24%. Joel Greenblatt would press for urgent turnaround measures.
-134.36%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-134.21%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-134.21%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.82%
Negative OCF growth while TRVN is at 37.31%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-141.82%
Negative FCF growth while TRVN is at 37.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.42%
Negative 10Y OCF/share CAGR while TRVN stands at 49.15%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31.42%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-183.28%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1.36%
Below 50% of TRVN's 60.68%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1.36%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
-52.35%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.38%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-12.67%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-28.84%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
60.35%
SG&A growth well above TRVN's 10.57%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.